Structures by: Doriguetto A. C.
Total: 62
Sulfamethoxazole bromide
C10H12N3O3S,Br
New Journal of Chemistry (2019) 43, 26 10250
a=14.2076(8)Å b=12.7070(6)Å c=15.2817(9)Å
α=90° β=92.703(5)° γ=90°
Sulfamethoxazole nitrate
C10H12N3O3S,NO3
New Journal of Chemistry (2019) 43, 26 10250
a=5.3927(4)Å b=31.353(2)Å c=7.8011(6)Å
α=90° β=99.399(8)° γ=90°
2(C13H10ClN5O5),H2O
2(C13H10ClN5O5),H2O
RSC Advances (2020) 10, 21 12384-12394
a=11.666(5)Å b=8.002(5)Å c=33.179(5)Å
α=90° β=99.513(5)° γ=90°
C21H18FeN4O2
C21H18FeN4O2
New Journal of Chemistry (2019) 43, 36 14257
a=19.016(16)Å b=12.875(8)Å c=7.696(5)Å
α=90° β=90° γ=90°
C41H36ClN2OP2Ru,F6P
C41H36ClN2OP2Ru,F6P
New J. Chem. (2017)
a=12.4950(4)Å b=16.3401(6)Å c=19.2663(6)Å
α=90° β=101.085(2)° γ=90°
2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide
C14H11ClN2O4S
CrystEngComm (2013) 15, 19 3767
a=8.1051(3)Å b=7.1178(3)Å c=12.2732(5)Å
α=90° β=103.646(4)° γ=90°
Ticlopidine hydrochloride form II
C14H15Cl2NS
CrystEngComm (2011) 13, 19 5737
a=5.4410(2)Å b=12.2260(4)Å c=21.7050(7)Å
α=90° β=101.040(2)° γ=90°
Chlortalidone Form IV
4(C14H11ClN2O4S),CHCl3
CrystEngComm (2012) 14, 19 6173
a=7.763(2)Å b=12.938(5)Å c=17.221(7)Å
α=72.48(2)° β=87.107(16)° γ=86.201(17)°
Doxycycline monohydrate
C22H24N2O8,H2O
CrystEngComm (2012) 14, 7 2532
a=5.9241(1)Å b=9.4808(2)Å c=18.5568(4)Å
α=90.00° β=91.192(2)° γ=90.00°
C48H32Cu2N12O4,2(NO3),5(H2O)
C48H32Cu2N12O4,2(NO3),5(H2O)
CrystEngComm (2017)
a=22.185(4)Å b=18.725(4)Å c=23.730(5)Å
α=90° β=102.68(3)° γ=90°
C37H36ClCu2N8O11,ClO4,0.139(O2),0.721(O)
C37H36ClCu2N8O11,ClO4,0.139(O2),0.721(O)
CrystEngComm (2017)
a=12.7715(5)Å b=13.2527(5)Å c=14.5883(5)Å
α=116.2400(10)° β=101.3600(10)° γ=95.4720(10)°
Ct-[RuCl(CO)(dppb)(bipy)]PF6
C39H36ClF6N2OP3Ru
New J. Chem. (2017)
a=14.6581(2)Å b=16.2338(2)Å c=16.5500(2)Å
α=90° β=92.7590(10)° γ=90°
C18H26CuMnN2O9S3,C2H6OS
C18H26CuMnN2O9S3,C2H6OS
Dalton transactions (Cambridge, England : 2003) (2011) 40, 3 746-754
a=8.5580(11)Å b=10.1730(15)Å c=18.201(6)Å
α=93.146(17)° β=98.93(2)° γ=110.158(14)°
MnCu(dmopba)(H2O)3.4H2O
C12H22CuMnN2O13
Dalton transactions (Cambridge, England : 2003) (2011) 40, 3 746-754
a=8.4666(3)Å b=10.5796(5)Å c=10.7969(4)Å
α=89.873(4)° β=95.912(4)° γ=93.725(2)°
C46H44Cu2N2O8S
C46H44Cu2N2O8S
Dalton transactions (Cambridge, England : 2003) (2015) 45, 1 172-189
a=9.8067(4)Å b=11.9518(5)Å c=19.7047(7)Å
α=83.844(3)° β=79.762(3)° γ=69.662(4)°
C20H20CuNO4
C20H20CuNO4
Dalton transactions (Cambridge, England : 2003) (2015) 45, 1 172-189
a=17.8636(3)Å b=7.9173(2)Å c=25.9511(6)Å
α=90° β=93.810(2)° γ=90°
C28H27CuN2O5S,1(O)
C28H27CuN2O5S,1(O)
Dalton transactions (Cambridge, England : 2003) (2015) 45, 1 172-189
a=23.9841(6)Å b=5.88310(10)Å c=41.7264(13)Å
α=90° β=106.501(3)° γ=90°
C26H26CuN5NaO8
C26H26CuN5NaO8
Dalton transactions (Cambridge, England : 2003) (2015) 45, 1 172-189
a=10.024(5)Å b=10.824(5)Å c=12.846(5)Å
α=97.185(5)° β=90.782(5)° γ=104.175(5)°
Olex2 1.2-beta(compiled 2014.05.21 svn.r2942 for OlexSys, GUI svn.r4844)
C120H126Cu6N6O21
Dalton transactions (Cambridge, England : 2003) (2015) 45, 1 172-189
a=13.3056(15)Å b=18.004(2)Å c=47.337(5)Å
α=90° β=96.278(4)° γ=90°
(nBu4N)2[Cu{Cu(dnopba)}2](dmso)4
C30H50Cu1.5N5O12S2
Dalton transactions (Cambridge, England : 2003) (2014) 43, 39 14586-14595
a=10.6674(4)Å b=13.1267(5)Å c=14.6733(6)Å
α=85.761(3)° β=77.173(3)° γ=68.322(4)°
(nBu4N)2[Cu{Cu(Cl2opba)}2](dmso)4
C30H50Cl2Cu1.5N3O8S2
Dalton transactions (Cambridge, England : 2003) (2014) 43, 39 14586-14595
a=10.0700(2)Å b=12.8470(3)Å c=15.5580(4)Å
α=87.975(2)° β=76.087(2)° γ=69.626(1)°
Lead Barium Zirconium Titanium Oxide
Pb0.9Ba0.1Zi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=5.78826(5)Å b=5.78826(7)Å c=14.27227(16)Å
α=90.00000° β=90.00000° γ=120.00000°
Lead Barium Zirconium Titanium Oxide
Pb0.9Ba0.1Zi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=4.10755(3)Å b=4.10755(3)Å c=4.10755(3)Å
α=90.00000° β=90.00000° γ=90.00000°
Lead Barium Zirconium Titanium Oxide
Pb0.8Ba0.2Zi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=5.79776(5)Å b=5.79776(5)Å c=14.26758(15)Å
α=90.00000° β=90.00000° γ=120.00000°
Lead Barium Zirconium Titanium Oxide
Pb0.8Ba0.2Zi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=4.111610(17)Å b=4.111610(17)Å c=4.111610(17)Å
α=90.00000° β=90.00000° γ=90.00000°
Lead Barium Zirconium Titanium Oxide
Pb0.7Ba0.3Zi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=4.11241(6)Å b=4.11241(6)Å c=4.11241(6)Å
α=90.00000° β=90.00000° γ=90.00000°
Lead Barium Zirconium Titanium Oxide
Pb0.6Ba0.4Zi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=4.11604(2)Å b=4.11604(2)Å c=4.11604(2)Å
α=90.00000° β=90.00000° γ=90.00000°
Lead Zirconium Titanium Oxide
PbZi0.65Ti0.35O3
Acta Crystallographica, Section B (2007) 63, 5 713-718
a=5.7779174(9)Å b=5.7779174(9)Å c=14.26920510(15)Å
α=90.00000° β=90.00000° γ=120.00000°
Lead Zirconium Titanium Oxide
PbZi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=4.09836(3)Å b=4.09836(3)Å c=4.09836(3)Å
α=90.00000° β=90.00000° γ=90.00000°
P-nitrobenzylidene-p-phenylaminoaniline
C19H15N3O2
Acta crystallographica Section B, Structural science, crystal engineering and materials (2015) 71, Pt 4 416-426
a=10.3885(3)Å b=16.7902(4)Å c=8.9064(2)Å
α=90° β=97.704(2)° γ=90°
2,4-dinitrobenzylidene-p-phenylaminoaniline
C19H14N4O4
Acta crystallographica Section B, Structural science, crystal engineering and materials (2015) 71, Pt 4 416-426
a=6.5715(2)Å b=15.0533(4)Å c=17.0598(5)Å
α=90° β=90° γ=90°
P-nitrobenzylidene-p-diethylaminoaniline
C17H19N3O2
Acta crystallographica Section B, Structural science, crystal engineering and materials (2015) 71, Pt 4 416-426
a=16.1019(5)Å b=7.6028(3)Å c=12.3616(4)Å
α=90° β=91.615(3)° γ=90°
5-nitro-2-furaldehyde N-(hydroxymethyl)semicarbazone
C7H8N4O5
Acta Crystallographica Section E (2005) 61, 7 o2099-o2101
a=10.3757(5)Å b=10.8125(5)Å c=16.9455(8)Å
α=90° β=92.095(3)° γ=90°
Methyl katononate
C31H48O3
Acta Crystallographica Section E (2003) 59, 2 o164-o166
a=12.0144(4)Å b=7.2750(4)Å c=30.364(2)Å
α=90° β=99.565(2)° γ=90°
Ent-5α,15α-epoxy-9,10-friedo-10β,11β-dihydroxy-16,11α:19,10β-disecco-17- norkauran-16,19-dioic acid 16\ρightarrow11:19\ρightarrow10-dilactone
C19H24O5
Acta Crystallographica Section E (2002) 58, 12 o1392-o1394
a=6.6980(2)Å b=13.6063(3)Å c=17.2155(5)Å
α=90° β=90° γ=90°
Succinyl isoniazid
C10H11N3O4
Acta Crystallographica Section E (2003) 59, 3 o288-o289
a=4.8140(2)Å b=8.9168(4)Å c=12.4943(6)Å
α=83.797(2)° β=79.735(2)° γ=81.035(2)°
2-N,N-dimethylamino-6-hydroxy-1,4-naphthoquinone
C12H11NO3
Acta Crystallographica Section C (1999) 55, 4 639-642
a=13.6570(10)Å b=14.4640(10)Å c=11.0140(10)Å
α=90° β=112.104(3)° γ=90°
Franklinite
Zn0.68Mn0.36Fe1.96O4
Acta Crystallographica Section C (1999) 55, 11 1751-1753
a=8.4551(3)Å b=8.4551(3)Å c=8.4551(3)Å
α=90° β=90° γ=90°
Methyl-p-aminobenzoate
C8H9NO2
Acta Crystallographica Section C (2004) 60, 1 o69-o71
a=8.5969(4)Å b=5.6053(2)Å c=15.5397(7)Å
α=90° β=96.172(2)° γ=90°
Terebic acid
C7H10O4
Acta Crystallographica Section C (2012) 68, 8 o294-o297
a=5.9890(10)Å b=5.6630(10)Å c=22.2820(10)Å
α=90.00° β=97.070(10)° γ=90.00°
2-(2-oxothiazolidin-3-yl)-4,5-dihydrothiazolium hydrogen sulfate monohydrate
C6H9N2OS2,HO4S,H2O
Acta Crystallographica Section C (2008) 64, 7 o395-o397
a=5.8508(2)Å b=13.0999(4)Å c=15.4187(5)Å
α=90° β=90° γ=90°
Mammeigin
C25H24O5
Acta Crystallographica Section C (2006) 62, 6 o350-o352
a=16.7270(10)Å b=14.1520(10)Å c=8.7180(10)Å
α=90° β=90.790(10)° γ=90°
6-dehydroxyjacareubin
C18H14O5
Acta Crystallographica Section C (2001) 57, 9 1095-1097
a=7.4450(2)Å b=9.5200(3)Å c=10.9390(3)Å
α=105.051(2)° β=103.154(2)° γ=93.083(2)°
2-mercaptothiazoline
C3H5NS2
Acta Crystallographica Section C (2006) 62, 3 o115-o117
a=5.4845(2)Å b=6.4997(3)Å c=7.6758(3)Å
α=84.121(2)° β=73.816(3)° γ=71.792(3)°
Magnesium aluminum iron chromite
Al0.41Cr1.42Fe0.65Mg0.40O4.00
Acta Crystallographica Section C (2005) 61, 3 i27-i28
a=8.31058(5)Å b=8.31058(5)Å c=8.31058(5)Å
α=90.00° β=90.00° γ=90.00°
Lupeol
C30H50O
Acta Crystallographica Section C (2009) 65, 3 o97-o99
a=19.1006(14)Å b=19.1006(14)Å c=7.2128(4)Å
α=90° β=90° γ=90°
3,4-dihydroxybenzophenone monohydrate
C13H10O3,H2O
Acta Crystallographica Section C (2010) 66, 9 o463-o465
a=4.29200(10)Å b=23.2084(7)Å c=11.4552(3)Å
α=90° β=95.393(2)° γ=90°
2,2',4,4'-tetrahydroxybenzophenone dihydrate
C13H10O5,2(H2O)
Acta Crystallographica Section C (2012) 68, 4 o156-o159
a=15.1394(4)Å b=7.7629(3)Å c=11.0690(4)Å
α=90° β=100.628(2)° γ=90°
Methyl 4-(piperidin-1-ylcarbonyl)benzoate
C14H17NO3
Acta Crystallographica Section E (2010) 66, 7 o1630
a=5.879(5)Å b=9.693(5)Å c=12.190(5)Å
α=69.684(5)° β=82.535(5)° γ=77.502(5)°
4-{[4-(Hydroxymethyl)piperidin-1-yl]methyl}phenol
C13H19N1O2
Acta Crystallographica Section E (2012) 68, 7 o2275-o2276
a=6.0428(2)Å b=17.2269(7)Å c=11.3010(4)Å
α=90.000° β=94.663(4)° γ=90.000°
Doxycycline nitrate salt hemihydrate
2(C22H25N2O8)1,2(N1O3)1,1(O1H2)
Crystal Growth & Design (2014) 14, 8 3711
a=8.0679(2)Å b=8.9156(3)Å c=16.6791(5)Å
α=77.872(2)° β=87.581(2)° γ=74.133(3)°
Doxycycline acetic acid dihydrate
C22H24N2O8,2(O1H2),1(C2O2H4)
Crystal Growth & Design (2014) 14, 8 3711
a=6.4753(2)Å b=9.0970(4)Å c=42.8077(16)Å
α=90° β=90° γ=90°
Lamivudine double strand
C75H114Cl2N24O37S8
Crystal Growth & Design (2010) 10, 2 676
a=14.22190(20)Å b=25.60790(29)Å c=15.17540(20)Å
α=90.00° β=117.4652(5)° γ=90.00°
Didanosine
C10H12N4O3,0.125H2O
Crystal Growth & Design (2010) 10, 4 1885
a=7.277(1)Å b=10.052(2)Å c=14.476(3)Å
α=90.000° β=93.71(1)° γ=90.000°
Hexagram-Type Topology Lamivudine Duplex
3(C8H11N3O3S),2(H2O)
Crystal Growth & Design (2012) 12, 10 5138
a=14.550(1)Å b=14.550(1)Å c=29.538(3)Å
α=90.00° β=90.00° γ=120.00°
Lamivudine hemihydrochloride hemihydrate
C8H12N3O3S,C8H11N3O3S,H2O,Cl
Crystal Growth & Design (2012) 12, 10 5138
a=6.972(5)Å b=12.167(7)Å c=13.867(8)Å
α=100.52(3)° β=93.15(4)° γ=91.43(4)°
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-(1H)-pyrimidin-2-one maleate
C8H12N3O3S,C4H3O4
Crystal Growth & Design (2009) 9, 12 5283
a=5.4584(3)Å b=12.8761(8)Å c=21.8161(13)Å
α=90.00° β=90.00° γ=90.00°
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-(1H)-pyrimidin-2-one maleate
C8H12N3O3S,C4H3O4
Crystal Growth & Design (2009) 9, 12 5283
a=5.4130(1)Å b=12.7870(4)Å c=21.6501(7)Å
α=90.00° β=90.00° γ=90.00°
Chlortalidone Form I
C14H11ClN2O4S
Crystal Growth & Design (2009) 9, 7 3235
a=6.2270(2)Å b=8.3870(3)Å c=14.3640(4)Å
α=92.141(2)° β=101.050(2)° γ=107.024(2)°
Chlortalidone Form III
C14H11ClN2O4S
Crystal Growth & Design (2009) 9, 7 3235
a=7.9957(2)Å b=8.1467(2)Å c=11.4761(3)Å
α=80.448(2)° β=79.277(2)° γ=86.106(2)°
Doxycycline chloride salt dihydrate
C22H25N2O81,2(H2O1),Cl11)
Crystal Growth & Design (2014) 14, 8 3711
a=11.0979(1)Å b=12.7557(1)Å c=16.8829(2)Å
α=90° β=90° γ=90°
Menezesite
Ba2.21Ca0.31Fe0.23H48K0.53Mg0.935Mn0.23Nb9.22O54Ta0.36Th0.55Ti3.25Zr2.74
American Mineralogist (2008) 93, 81-87
a=13.017Å b=13.017Å c=13.017Å
α=90° β=90° γ=90°